Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ephedrine 8 mg dose limit, warnings against long-term intake proposed by agency.

This article was originally published in The Tan Sheet

Executive Summary

EPHEDRINE ALKALOID PER-SERVING LIMIT OF 8 MG SUGGESTED BY FDA in a proposed rule published in the June 4 Federal Register. The rule is directed at dietary supplement products containing ephedrine alkaloids derived from raw botanicals -- products usually labeled as containing "ephedra," "Chinese ephedra" or "ma huang" that are sold for weight loss, increased energy and body building. The proposal does not apply to OTC drugs.

You may also be interested in...



Consumer Reports Article Highlights “Dangerous” Supplements

The dietary supplement industry faces more negative publicity after a Consumer Reports article dubbed twelve supplements the "dirty dozen" that consumers should avoid

Consumer Reports Article Highlights “Dangerous” Supplements

The dietary supplement industry faces more negative publicity after a Consumer Reports article dubbed twelve supplements the "dirty dozen" that consumers should avoid

Consumer Reports Article Highlights “Dangerous” Supplements

The dietary supplement industry faces more negative publicity after a Consumer Reports article dubbed twelve supplements the "dirty dozen" that consumers should avoid

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS087147

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel